Personalized Nanomedicine: A Revolution at the Nanoscale
暂无分享,去创建一个
[1] Martin G Pomper,et al. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[2] Robert J. Gillies,et al. A microenvironmental model of carcinogenesis , 2008, Nature Reviews Cancer.
[3] R. Coleman,et al. Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model. , 2016, Gynecologic oncology.
[4] S. Mitragotri,et al. Nanoparticles in the clinic , 2016, Bioengineering & translational medicine.
[5] S. Moghimi,et al. Defining and characterizing non-biological complex drugs (NBCDs) – Is size enough? The case for liposomal doxorubicin generics (‘liposomal nanosimilars’) for injection , 2014 .
[6] Yana K Reshetnyak,et al. Advanced targeted nanomedicine. , 2015, Journal of biotechnology.
[7] L. Boros,et al. Acidosis induces reprogramming of cellular metabolism to mitigate oxidative stress , 2013, Cancer & metabolism.
[8] Benjamin C. Tang,et al. Managing diabetes with nanomedicine: challenges and opportunities , 2014, Nature Reviews Drug Discovery.
[9] Young Jik Kwon,et al. "Combo" nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. , 2016, Advanced drug delivery reviews.
[10] P. Soon-Shiong,et al. SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. , 2009, Translational oncology.
[11] V. Weissig,et al. Nanopharmaceuticals (part 2): products in the pipeline , 2015, International journal of nanomedicine.
[12] T. Golub,et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.
[13] A. Stegh. Toward personalized cancer nanomedicine - past, present, and future. , 2013, Integrative biology : quantitative biosciences from nano to macro.
[14] Mingying Yang,et al. Phage-Enabled Nanomedicine: From Probes to Therapeutics in Precision Medicine. , 2017, Angewandte Chemie.
[15] Tracy K. Pettinger,et al. Nanopharmaceuticals (part 1): products on the market , 2014, International journal of nanomedicine.
[16] N. Gu,et al. The Smart Drug Delivery System and Its Clinical Potential , 2016, Theranostics.
[17] Christine Vauthier,et al. Polymer Nanoparticles for Nanomedicines , 2016, Springer International Publishing.
[18] D. V. Bazile,et al. Nanotechnologies in Drug Delivery - An Industrial Perspective , 2014 .
[19] R. Alemany,et al. A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel , 2017, Oncotarget.
[20] Glen J Weiss,et al. Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors , 2016, Clinical Cancer Research.
[21] Has nanomedicine lived up to its promise? , 2014, Nanotechnology.
[22] Deniz A. Bölükbas,et al. Lung cancer nanomedicine: potentials and pitfalls. , 2015, Nanomedicine.
[23] R. Hayeshi,et al. State of the art and future directions in nanomedicine for tuberculosis , 2013, Expert opinion on drug delivery.
[24] G. Ponchel,et al. Polymer Nanoparticles for Nanomedicines. A Guide for their Design, Preparation and Development. , 2017, Anticancer research.
[25] W J Stark,et al. Industrial applications of nanoparticles. , 2015, Chemical Society reviews.
[26] Ö. Türeci,et al. Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination , 2015, Journal of immunology research.
[27] I. Chourpa,et al. Optimization of iron oxide nanoparticles encapsulation within poly(d,l-lactide-co-glycolide) sub-micron particles. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[28] J. B. Hall,et al. Characterization of nanoparticles for therapeutics. , 2007, Nanomedicine.
[29] Kristofer J. Thurecht,et al. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date , 2016, Pharmaceutical Research.
[30] Dong Soo Lee,et al. Nanomedicine: Past, present and future - A global perspective. , 2015, Biochemical and biophysical research communications.
[31] Morteza Mahmoudi,et al. Protein-Nanoparticle Interactions , 2013 .
[32] Amber Hoskins. Genetic and Rare Diseases Information Center (CARD) , 2006, Medical reference services quarterly.
[33] J. Benoit,et al. Brain targeting using novel lipid nanovectors. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[34] Thomas S. Woodson. Public private partnerships and emerging technologies: A look at nanomedicine for diseases of poverty , 2016 .
[35] Xiaoyang Xu,et al. Cancer Nanomedicine: From Targeted Delivery to Combination Therapy , 2015, Trends in molecular medicine.
[36] S. Svenson,et al. What nanomedicine in the clinic right now really forms nanoparticles? , 2014, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[37] A. Shelling,et al. Nanoparticle therapeutics: Technologies and methods for overcoming cancer. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[38] Finbarr Murphy,et al. Impact and effectiveness of risk mitigation strategies on the insurability of nanomaterial production: evidences from industrial case studies , 2015, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[39] E. Shapiro,et al. Magnetic poly(lactide‐co‐glycolide) and cellulose particles for MRI‐based cell tracking , 2011, Magnetic resonance in medicine.
[40] Y. Pathak,et al. Drug Delivery Nanoparticles Formulation and Characterization , 2009 .
[41] Shannon Fischer,et al. Regulating nanomedicine: new nano tools offer great promise for the future-if regulators can solve the difficulties that hold development back , 2014, IEEE Pulse.
[42] S. Parveen,et al. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. , 2006, Clinical pharmacokinetics.
[43] Yang Sun,et al. Superparamagnetic PLGA-iron oxide microcapsules for dual-modality US/MR imaging and high intensity focused US breast cancer ablation. , 2012, Biomaterials.
[44] V. Venditto,et al. Cancer nanomedicines: so many papers and so few drugs! , 2013, Advanced drug delivery reviews.
[45] Regulating nanomedicine. , 2007, Nature materials.
[46] Kenneth A Dawson,et al. Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. , 2013, Journal of the American Chemical Society.
[47] V. Torchilin,et al. Drug targeting. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[48] T. Xia,et al. Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.
[49] H. Karanth,et al. pH‐Sensitive liposomes‐principle and application in cancer therapy , 2007, The Journal of pharmacy and pharmacology.
[50] Spiros Vamvakas,et al. On the edge of new technologies (advanced therapies, nanomedicines). , 2011, Drug discovery today. Technologies.
[51] J. Reynolds,et al. Nanomedicine applied to translational oncology: A future perspective on cancer treatment. , 2016, Nanomedicine : nanotechnology, biology, and medicine.
[52] L. John Burbidgh,et al. Products to market , 1993 .
[53] P. Couvreur,et al. Nanomedicines and stroke: Toward translational research , 2015 .
[54] Jörg Huwyler,et al. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[55] R. Duncan,et al. Nanomedicine(s) under the microscope. , 2011, Molecular pharmaceutics.
[56] V. Préat,et al. PLGA-based nanoparticles: an overview of biomedical applications. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[57] R. Duncan,et al. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. , 2013, Nanomedicine.
[58] Wen Jiang,et al. Designing nanomedicine for immuno-oncology , 2017, Nature Biomedical Engineering.
[59] R. Gillies,et al. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. , 2011, Molecular pharmaceutics.
[60] J. Kreuter,et al. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? , 2014, Advanced drug delivery reviews.
[61] Sarah Hurst Petrosko,et al. Accelerating the Translation of Nanomaterials in Biomedicine. , 2015, ACS nano.
[62] J. Lovrić,et al. Nanotherapeutics in the EU: an overview on current state and future directions , 2014, International journal of nanomedicine.
[63] Nanobiotech in big pharma: a business perspective. , 2017, Nanomedicine.
[64] Cristina Fornaguera,et al. Methods for the In Vitro Characterization of Nanomedicines—Biological Component Interaction , 2017, Journal of personalized medicine.
[65] Luisa M Russell,et al. State-ofthe-Art in Design Rules for Drug Delivery Platforms : Lessons from FDA-approved Nanomedicines , 2014 .
[66] Peter D Brown,et al. Nanomedicine: a pharma perspective. , 2015, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[67] Michael D Kaminski,et al. Synthesis and characterization of highly-magnetic biodegradable poly(d,l-lactide-co-glycolide) nanospheres. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[68] Xue-Qing Zhang,et al. Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. , 2012, Advanced drug delivery reviews.
[69] Jennifer I. Hare,et al. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. , 2017, Advanced drug delivery reviews.
[70] Catarina Pinto Reis,et al. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. , 2006, Nanomedicine : nanotechnology, biology, and medicine.
[71] R. Bosetti. Cost-effectiveness of nanomedicine: the path to a future successful and dominant market? , 2015, Nanomedicine.
[72] Brenda Baggett,et al. Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. , 2003, Biochemical pharmacology.
[73] Arthur G Erdman,et al. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. , 2013, Nanomedicine : nanotechnology, biology, and medicine.
[74] Man Liu,et al. Nanomedicine Drug Development: A Scientific Symposium Entitled “Charting a Roadmap to Commercialization” , 2014, The AAPS Journal.
[75] N. Durán,et al. Nanopharmaceuticals as a solution to neglected diseases: Is it possible? , 2017, Acta tropica.
[76] Brian Godman,et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers , 2010, BMC health services research.
[77] B. Ruozi,et al. Nanomedicine and neurodegenerative disorders: so close yet so far , 2015, Expert opinion on drug delivery.